SCHEMBL5557447

SCHEMBL5557447

CC(C)(C)OC(=O)Nc1cc(F)c(Cl)cc1NC(=O)CC(=O)c1cccc(-c2ccncc2)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 4/20 0.48
AAK1 Q2M2I8 4/20 0.41
RIPK3 Q9Y572 1/20 0.39
AURKA O14965 2/20 0.38
HDAC3 O15379 2/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
ALDH1A1 P00352 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
MET P08581 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5556871 0.90 CYP17A1 (0.46) CYP17A1AAK1AURKAHDAC3HDAC1
SCHEMBL5562523 0.90 CYP17A1 (0.46) CYP17A1AAK1AURKAHDAC3HDAC1
SCHEMBL5564494 0.89 CYP17A1 (0.44) CYP17A1AAK1ALDH1A1MEN1KMT2A
SCHEMBL5559923 0.89 CYP17A1 (0.44) CYP17A1AAK1ALDH1A1MEN1KMT2A
SCHEMBL5562677 0.88 ALDH1A1 (0.43) CYP17A1HDAC3HDAC1HDAC2HDAC10
SCHEMBL5557702 0.88 CYP17A1 (0.39) CYP17A1AAK1HDAC3HDAC1HDAC2
SCHEMBL5558422 0.87 CYP17A1 (0.46) CYP17A1AAK1RIPK3AURKAHDAC3
SCHEMBL5557524 0.87 CYP17A1 (0.50) CYP17A1AAK1AURKAKMT2AMET
SCHEMBL5557260 0.84 CYP17A1 (0.50) CYP17A1AAK1AURKAHDAC3HDAC1
SCHEMBL5557461 0.84 CYP17A1 (0.46) CYP17A1AAK1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474416-B1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS HOFFMANN LA ROCHE (CH) 2007-09-26 EP disclosed
US-6949542-B2 Dihydro-benzo[b][1,4]diazepin-2-one derivatives HOFFMAN-LA ROCHE INC. (US) 2005-09-27 US disclosed
EP-1474416-A1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG (CH) 2003-09-04 US disclosed
WO-2003066623-A1 DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives CYP1B1, GRIN2B, CYP4B1 CYP17A1 942/4885AAK1 2928/4885RIPK3 4144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.